"One of the lessons for companies trying to develop drugs is to listen to what the FDA tells you, " says RichardGoldberg , a professor of oncology at the Mayo Clinic, who is helping Sanofi run clinical tests that finally prove that Eloxatin should be the first-line drug against colorectal cancer.